TB-500
Tissue Repair and Healing
ABOUT
TB-500 is a product/marketing name used inconsistently and must not be assumed to be the same substance as full-length thymosin beta-4 or any specific fragment. A clinical review lists it among unapproved peptide therapies, but does not establish evidence for a defined TB-500 product.
EVIDENCE OVERVIEW
Too little published work to judge either way
WHAT THIS MEANS
Insufficient evidence. Review the research and limitations before relying on this record.
IDENTITY
HALF-LIFE
HOW IT IS THOUGHT TO WORK
TB-500 is a short synthetic fragment corresponding to the actin-binding region of thymosin beta-4, not the whole 43-amino-acid protein. Thymosin beta-4 itself is an actin-monomer-sequestering protein, and the pleiotropic anti-inflammatory and repair effects attributed to it have not been traced to a defined receptor.
PHARMACOKINETICS
No human pharmacokinetic study of the fragment has been published; circulating half-life figures quoted commercially are extrapolations from molecular weight, not measurements. Pharmacokinetic data from full-length thymosin beta-4 trials do not transfer, because the molecules differ.
REVIEW
PUBLISHED PAIR RECORDS
with BPC-157
Commonly combined tissue-repair peptides with no combination evidenceBPC-157 and TB-500 are frequently used together for tissue repair, and this is one of the few combinations in this catalogue with any human report at all: a retrospective chart review of knee-pain patients administered both together. That report had no control group, no randomisation, and cannot separate the contribution of either peptide - so it documents that the combination has been used, not that it works. A 2025 systematic review found one clinical study against 35 preclinical animal studies for BPC-157. Neither compound has a published human pharmacokinetic profile, so no exposure-based reasoning about combining them is possible. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 21 Aug 2026with Thymosin Beta-4
Same molecule family: fragment and parent proteinTB-500 and thymosin beta-4 are not two agents - TB-500 is a short synthetic fragment corresponding to the actin-binding region of the 43-amino-acid thymosin beta-4 protein. Treating them as a combination assumes two mechanisms where the evidence describes one, and the two are routinely conflated in marketing material. The distinction that does matter runs the other way: human trial data exists for full-length thymosin beta-4 (a phase 1 study in healthy volunteers, an intravenous study after acute myocardial infarction, phase 2 topical eye drops) and none exists for the fragment, so pharmacokinetic and safety findings for the parent protein cannot be read across to TB-500. Both are prohibited at all times in sport, TB-500 by name. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 21 Aug 2026with KLOW
Same substance taken twice: blend already contains this compoundKLOW already contains TB-500 at 10 mg per vial. Scheduling the standalone compound alongside the blend means taking it twice from two sources, and the blend's other components come with it whether or not they are wanted at that moment. This is the one exposure risk a blend creates that its individual parts do not, and it is arithmetic rather than pharmacology - the combined amount is whatever the two products add up to. Where a blend's ratio is fixed by the manufacturer, the only way to change one component's dose is to add or remove the whole vial. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 25 Aug 2026with GLOW
Same substance taken twice: blend already contains this compoundGLOW already contains TB-500 at 10 mg per vial. Scheduling the standalone compound alongside the blend means taking it twice from two sources, and the blend's other components come with it whether or not they are wanted at that moment. This is the one exposure risk a blend creates that its individual parts do not, and it is arithmetic rather than pharmacology - the combined amount is whatever the two products add up to. Where a blend's ratio is fixed by the manufacturer, the only way to change one component's dose is to add or remove the whole vial. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 25 Aug 2026with Wolverine blend
Same substance taken twice: blend already contains this compoundWolverine blend already contains TB-500. Scheduling the standalone compound alongside the blend means taking it twice from two sources, and the blend's other components come with it whether or not they are wanted at that moment. This is the one exposure risk a blend creates that its individual parts do not, and it is arithmetic rather than pharmacology - the combined amount is whatever the two products add up to. Where a blend's ratio is fixed by the manufacturer, the only way to change one component's dose is to add or remove the whole vial. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 25 Aug 2026HUMAN EVIDENCE
Human trial data exists for full-length thymosin beta-4 - a phase 1 intravenous safety study after acute myocardial infarction, and phase 2 topical eye drops for dry eye disease - but not for the TB-500 fragment. The two are frequently conflated in marketing material. The only human report naming TB-500 is a retrospective chart review of 17 knee-pain patients in which it was given alongside BPC-157, so no effect can be attributed to either alone.
REPORTED EFFECTS
No systematic human safety data exists. Thymosin beta-4 and its derivatives, TB-500 named explicitly, are prohibited at all times under the WADA Prohibited List as growth factors affecting muscle, tendon or ligament regeneration; anti-doping laboratories run validated assays for the synthetic fragment. No regulator has approved this substance for the use described here, so there is no label-verified dose, purity standard, or safety monitoring requirement behind it.
RESEARCH LIMITATIONS
The source is contextual, not a formulation-specific trial. Evidence for thymosin beta-4, fragments, or other products must not be transferred here. No protocol or dosing guidance is provided.
CURATED SOURCES · 4